Skip to content

NPPV on Inflammatory Markers and Sleep in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery

Effects of Noninvasive Positive Pressure Ventilation on Inflammatory Markers, Sleep, Pulmonary Function and HRQoL in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery. A Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02409173
Enrollment
17
Registered
2015-04-06
Start date
2015-01-31
Completion date
2020-07-31
Last updated
2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Metabolic syndrome, Sleep disorders, Bariatric Surgery, Noninvasive ventilation, Inflammation, Quality of life

Brief summary

Obesity is currently one of the most serious public health problems. Its prevalence is increasing sharply in recent decades, even in developing countries, leading to global epidemiology condition. Metabolic syndrome (MS) consists of an association of metabolic and cardiovascular disorders including central obesity, insulin resistance, dyslipidemia and hypertension in the same patient. Obstructive sleep apnea (OSA) is a common clinical condition in more than 60% patients with MS. It is still controversial in the world scientific literature whether treatment of OSA with Noninvasive Positive Pressure Ventilation (NPPV) in severely obese patients with and without MS is effective. The NPPV effectively reverses hypoxemia in patients with OSA, therefore justified the hypothesis that NPPV will reduce insulin resistance, ghrelin and resistin and raise adiponectin levels in a group of severely obese individuals with and without MS undergoing bariatric surgery. Objectives: To investigate the effects of Noninvasive Positive Pressure Ventilation on inflammatory markers, sleep, pulmonary function, BMI reduction and health related quality of life in severe obese patients with and without metabolic syndrome undergone to bariatric surgery.

Detailed description

Obesity is currently one of the most serious public health problems. Its prevalence is increasing sharply in recent decades, even in developing countries, leading to global epidemiology condition. Metabolic syndrome (MS) consists of an association of metabolic and cardiovascular disorders including central obesity, insulin resistance, dyslipidemia and hypertension in the same patient. Obstructive sleep apnea (OSA) is a common clinical condition in more than 60% patients with MS. It is still controversial in the world scientific literature whether treatment of OSA with Noninvasive Positive Pressure Ventilation (NPPV) in severely obese patients with and without MS is effective. The NPPV effectively reverses hypoxemia in patients with OSA, therefore justified the hypothesis that NPPV will reduce insulin resistance, ghrelin and resistin and raise adiponectin levels in a group of severely obese individuals with and without MS undergoing bariatric surgery. Objectives: To investigate the effects of Noninvasive Positive Pressure Ventilation on inflammatory markers, sleep, pulmonary function, BMI reduction and health related quality of life in severe obese patients with and without metabolic syndrome undergone to bariatric surgery. Methods/Design: Will participate severe obese patients with and without MS, screened from the Bariatric Surgery Service of Santa Casa de Sao Paulo. The inclusion criteria are patients with morbid obesity grade III, with an indication of bariatric surgery and who have agreed to the study, signing an informed consent. Subjects with BMI above 55 kg / m², clinically significant or mental health concerns unstable, an unrealistic target postsurgical weight and/or unrealistic expectations of the surgical treatment will be excluded. Patients will use the NPPV pre and post bariatric surgery. The evaluation protocol will consist of clinical history, vital signs, anthropometric data, clinical analysis of blood and adipose inflammatory markers, lung function tests, polysomnography, sleep scales, cardiovascular risk and quality of life questionnaires. Patients will be evaluated before and after bariatric surgery, 90, 180 and 360 days.

Interventions

DEVICENoninvasive positive airway pressure flow generator device

Noninvasive positive airway pressure flow generator device.

PROCEDUREBariatric Surgery

Standard Roux-en-Y gastric bypass

Sponsors

Centro Universitário de Anapolis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* male and female patients aged 18 to 65 years, * grade III severe obesity (BMI ≥ 40 kg/m2) or ≥ 35 kg/m2 with comorbidities, * awaiting bariatric surgery, * with documented history of conventional weight loss attempts having proven unsuccessful over time, * sleep apnea history verified through polysomnography * and if they are able to understand and agreement to participate in the study through a signed term of informed consent.

Exclusion criteria

* Any medical condition rendering surgery too risky, * BMI above 55 kg/m2, * unrealistic postoperative target weight and/or unrealistic expectations of surgical treatment, * pregnancy, * lactation or planned pregnancy within two years of potential surgical treatment, * lack of safe access to abdominal cavity or gastrointestinal tract; * abusive alcohol use or drug use, * craniofacial abnormalities, * undergoing active treatment of sleep apnea, * cancer, * any cardiorespiratory condition opposite indicate the surgical procedure.

Design outcomes

Primary

MeasureTime frameDescription
Change in systemic immune responseBaseline immune response to 180 days.Systemic markers of inflammation through fasting blood samples biochemical indexes.
Change in systemic adipose inflammation responseBaseline adipose inflammation response to 180 days.Systemic markers of inflammation through biochemical indexes in visceral (omental, mesenteric) and subcutaneous adipose tissue depots.

Secondary

MeasureTime frameDescription
Changes in maximal ventilatory pressures180 daysAssess maximal inspiratory and expiratory pressures through manovacuometry.
Prevalence of sleep disorders180 daysStudy sleep patterns through full standard polysomnography.
Weight Loss180 daysBody mass index reduction.
Changes in health related quality of life180 daysChanges in quality of life through Short Form-36 and BAROS questionnaires.
Changes in pulmonary function180 daysAssess pulmonary function through pletysmography.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026